Topic Lifecycle: Dormant
This topic is currently dormant in the news cycle. It was last covered on Thursday 24 September 2026 and has not appeared in recent broadcasts.
Coverage trend (last 30 days)
How much coverage this topic got from each channel over the past month.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Recent stories
The latest story timelines linked to this topic, newest activity first.
What was reported
A plain summary of this topic, built from the channels that covered it.
Both channels reported that Enhertu, a drug for a specific type of incurable breast cancer, has been made available on the NHS in England after a previous rejection on cost-effectiveness grounds. Clinical trials indicate it can extend life by about seven months on average, and around one thousand women a year are expected to benefit. The reversal came after a change in funding arrangements; BBC attributed this to a UK-US trade deal that increased medicine spending by 25%, while Sky described it as a funding arrangement. The drug had already been available in Scotland and other countries. Sky also noted it is the first targeted treatment of its kind for this cancer, and reported that charities called for approval in Wales and Northern Ireland. BBC's coverage included a patient's story and campaign efforts.
Key Claims by Channel
Tuesday 4 August 2026
| Claim | Channel 5 | BBC News | BBC One | ITV |
|---|---|---|---|---|
| Current breast cancer screening could miss 95% of high-risk women under 50. | ||||
| Guidelines should consider lifestyle factors like alcohol and obesity instead of only family history. | · | · | · | |
| The study was conducted by researchers at the University of Cambridge. | · | |||
| Current screening criteria for women under 50 rely primarily on family history of breast cancer. | · | |||
| A new risk calculator combines family history with lifestyle factors such as alcohol intake, obesity, and whether a woman has had children. | · | · | ||
| Only 5 to 10% of breast cancer cases are linked to inherited genes. | · | · | ||
| Using the new risk tool could lead to more false alarms and increased anxiety, and would require balancing benefits against NHS resources. | · | · | ||
| The NHS currently lacks the resources to support the additional women who would be identified as at risk through such a tool. | · | · | · | |
| A new risk assessment tool identified eight times as many women who went on to develop breast cancer. | · | |||
| 73% of women under 50 who develop breast cancer within a decade had no family history. | · | · | · | |
| 96% of breast cancer cases occur in women over 40. | · | · | ||
| NICE stated that current evidence does not warrant a change to screening guidelines. | · | · | · | |
| Up to a quarter of all women under 50 would be classified as high risk under the new model. | · | · | · |
Thursday 17 September 2026
| Claim | Channel 5 | BBC One | Sky News |
|---|---|---|---|
| NHS England reversed its 2024 decision to reject Enhertu, which was initially due to cost effectiveness concerns. | |||
| Clinical trials showed Enhertu can extend patients' lives by about seven months compared with chemotherapy alone. | · | ||
| Enhertu had been approved in Scotland for two years before its approval in England. | |||
| Wales is expected to make the drug available shortly, while the guidance does not automatically apply to Northern Ireland. | · | · | |
| Enhertu is now available on the NHS in England for a specific type of incurable breast cancer. | · | ||
| Around one thousand women per year are expected to benefit from Enhertu's availability. | · | ||
| The reversal followed a new funding arrangement, reportedly including a US trade deal with a 25% increase in medicines spending. | · | ||
| Enhertu is the first targeted treatment of its kind for this type of cancer. | · | · | |
| Charities described the decision as monumental progress and called for the drug to be approved in Wales and Northern Ireland. | · | · |
This is a cross-channel consensus summary, not an objective account. Consensus can be uniformly wrong, or omit what only one channel covered.
Timeline
Where this topic appeared. Cells show coverage time and are darker when there was more coverage.
| Date | Channel 5 | BBC News | BBC One | BBC Two | Channel 4 | GB News | ITV | Sky News |
|---|---|---|---|---|---|---|---|---|
| Thursday 24 September 2026 | — | — | 4m 5s 2.7% | — | — | — | — | — |
| Thursday 17 September 2026 | — | — | 5m 49s 3.9% | — | — | — | — | 2m 2s 2.0% |
| Tuesday 8 September 2026 | 3m 55s 13.2% | — | — | — | — | — | — | — |
| Tuesday 1 September 2026 | 3m 7s 8.5% | — | — | — | — | — | — | — |
| Tuesday 4 August 2026 | 7m 1s 17.7% | 2m 59s 3.1% | 5m 34s 5.7% | — | — | — | 5m 53s 11.9% | — |
| Monday 6 July 2026 | — | — | — | — | — | — | 3m 33s 5.7% | — |